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New York, NY; Chapel Hill, NC; Springfield, Mass; Seattle, Wash; and Indianapolis, IndLower extremity venous insufficiency is a common
medical condition that afflicts approximately 25% of
women and 15% of men.1 Great saphenous vein (GSV)
reflux is the most common underlying cause of symptom-
atic varicose veins. An increasingly popular alternative to
traditional surgical stripping of the GSV for management of
saphenous vein reflux is endovenous ablation (EVA) of that
vein using laser energy, radiofrequency-generated thermal
energy, or a chemical sclerosant.2-9 Comparative studies
evaluating long-term EVA clinical treatment outcomes, the
optimal timing of adjunctive procedures, and the relative
impact of anatomic location, size, length, and energy dep-
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582osition in the treated segment are expected in the near
future. This document provides recommended reporting
standards for physicians performing clinical research studies
evaluating EVA in the treatment of lower extremity venous
reflux and is thereby expected to facilitate comparison
between the results of different studies and to improve the
overall quality of clinical research on venous disease. These
standards have been developed by The Society of Interven-
tional Radiology (SIR) and The American Venous Forum
and were approved by the SIR Executive Council on Feb-
ruary 28, 2007, and by the AVF Executive Council on
February 13, 2007.
POPULATION DESCRIPTION
The general description of the population from which
studied groups were selected should be presented. This
should include the total number of patients seen and
treated at participating institutions during the study period,
patients’ gender and age distribution, and frequencies of
major treatment modalities used.
For studies including patients with bilateral disease,
both the number of patients and the number of treated
limbs, and whether limbs were treated concomitantly or
staged must be stated. Baseline patient characteristics
should include the level II basic CEAP10 classification
(Table I).
Severity of the disease should be reported using vali-
dated scales. The Venous Clinical Severity Score (VCSS,
Table II) is highly recommended as a measure of overall
disease severity.11,12 Use of both generic and venous
disease-specific measures is the accepted standard for study-
ing quality-of-life (QOL) changes. The Venous Insuffi-
CEA
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Life (VEINES-QOL/Sym) questionnaire scale, the
Chronic Venous Insufficiency Questionnaire-2 (CIVIQ-
2), and the Aberdeen questionnaires have all been validated
in patients with lower extremity venous reflux and are
highly recommended for use as venous disease–specific
QOL measures.13-19
Because patient satisfaction depends upon addressing
his or her chief complaint, the specific primary reason for
treatment is also important to indicate. Common symp-
toms of venous disease include aching, burning, itching,
heaviness, swelling, cramping, and local inflammation in
the affected limb, among others.
A history of superficial or deep venous disease or inter-
ventions, or both, may influence both the performance and
the results of EVA procedures and is therefore important to
describe. Specifically, the following interventions are im-
portant: use of graduated compression stockings; a history
Table I. CEAP classification of chronic venous disease
Classification
Clinical
C0 No visible or palpable signs of v
C1 Telangiectases or reticular veins
C2 Varicose veins
C3 Edema
C4a Pigmentation or eczema
C4b Lipodermatosclerosis or atroph
C5 Healed venous ulcer
C6 Active venous ulcer
S Symptomatic, including ache, p
complaints attributable to ve
A Asymptomatic
Etiologic
Ec Congenital
Ep Primary
Es Secondary (postthrombotic)
En No venous cause identified
Anatomic
As Superficial veins
Ap Perforator veins
Ad Deep veins
An No venous location identified
Pathophysiologic
Pr Reflux
Po Obstruction
Pr,o Reflux and obstruction
Pn No venous pathophysiology ide
Level of investigation
Level I Office visit, with history and cli
scanner.
Level II Noninvasive vascular laboratory
some plethysmographic meth
Level III Invasive investigations or more
venography, venous pressure
imaging.
Example A patient has painful swelling o
ulceration. Duplex scanning
knee, incompetent calf perfo
are no signs of postthrombot
Classification according to basicof venous stripping and/or ligation of truncal veins, ambu-latory phlebectomy, sclerotherapy, subfascial endoscopic
perforator surgery (SEPS), previous EVA procedures,
thrombolysis, angioplasty, or stent placement; or the pres-
ence of endovenous devices including stents, inferior vena
cava filters, and central venous access devices.
The presence of major comorbidities may reduce the
clinical success rate or increase the rate of complications, or
both. Conversely, exclusion of patient subsets due to mor-
bidity can also bias the population and should be consid-
ered when comparing patient cohorts. The following co-
morbidities may influence the results of EVA and should be
reported: coronary artery disease, congestive heart failure,
diabetes mellitus, thrombophilias, increased body mass in-
dex, and poor overall general health.20
Additional anatomic and physiologic characteriza-
tion of venous disease. Potential candidates for EVA
include patients with reflux in an incompetent GSV or small
saphenous vein (SSV) or in a major tributary branch of the
Symptom
s disease
nche
ightness, skin irritation, heaviness, and muscle cramps, and other
dysfunction
ble
examination, which may include the use of a hand-held Doppler
ng, which now routinely includes duplex color scanning, with
ded as desired
lex imaging studies, including ascending and descending
urements, computed tomography, or magnetic resonance
leg, and varicose veins, lipodermatosclerosis, and active
s axial reflux of the great saphenous vein above and below the
veins, and axial reflux in the femoral and popliteal veins. There
struction.
P: C6,S, Ep, As,p,d, Pr. (2004-05-17, L II).enou
ie bla
ain, t
nous
ntifia
nical
testi
od ad
comp
meas
f the
show
rator
ic obGSV or SSV such as the anterior thigh circumflex vein,
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Therefore, the presence of reflux in these veins is important
to document using duplex ultrasound imaging, as pertain-
ing to the CEAP A5 nonsaphenous category. Use of the
nomenclature recommended by the International Union of
Phlebology, the International Federation of Associations of
Anatomists, and the Federative International Committee
on Anatomical Terminology is expected.21,22
Variations to standard venous anatomy, when observed
on the ultrasound examination, should be reported. These
include tortuosity of the target vein, duplications, atresia,
the presence of anatomic venous variants, or variable ter-
mination of the SSV. The diameter of the GSV and SSV,
2 cm of the junction with the deep vein (common femo-
ral or popliteal) and target vein (if not the GSV or SSV)
should be measured. The patient position and site of treat-
ment should be specified.
Although a combination of a directed physical exami-
nation and duplex ultrasound imaging (CEAP level II
examination) is usually sufficient to characterize the ana-
tomic and physiologic extent of lower extremity venous
disease,23 diagnosis of chronic venous disorders can also be
supported by direct or indirect physiologic tests.24,25When
these tests are obtained, the results should be reported.
Similarly, when a CEAP level III examination is performed
using computed tomography or magnetic resonance imag-
ing, the reason for their use should be specified, the results
should be reported, and the specific criteria used for diag-
Table II. Venous Clinical Severity Score
Attribute Absent  0 Mild
Pain None Occasional, n
activity or
analgesics
Varicose veins None Few, scattere
varicose ve
Venous edema None Evening ank
Skin pigmentation None or focal, low
intensity (tan)
Diffuse, but
area and o
Inflammation None Mild celluliti
marginal a
ulcer
Induration None Focal, circum
(5 cm)
Active ulcers, n 0 1
Active ulceration duration None 3 months
Active ulcer, size None 2 cm diam
Compressive therapy Not used or not
compliant
Intermittent
stockings
GSV, Great saphenous vein; SSV, small saphenous veinnosis of venous abnormalities should be indicated.Terminology and definitions. Definitions of clinical
signs and symptoms should comply with definitions pre-
sented in the revised CEAP classification.10
Use of the nomenclature recommended by the Inter-
national Union of Phlebology, the International Feder-
ation of Associations of Anatomists, and the Federative
International Committee on Anatomical Terminology is
expected.21,22 Specific recommendations include the
terms great saphenous vein or GSV (instead of long
saphenous vein, greater saphenous vein, or internal sa-
phenous vein) and small saphenous vein or SSV (instead
of short saphenous vein, lesser saphenous vein, or exter-
nal saphenous vein).
The ultrasound criteria used to define reflux should be
indicated; in current practice, most vascular laboratories
consider the presence of venous flow reversal for 0.5 to
1.0 seconds with proximal compression, Valsalva maneu-
ver, or distal compression and release to represent patho-
logic reflux.23,26
TREATMENT DESCRIPTION
Pretreatment preparation. The aspects of pretreat-
ment preparation that may influence EVA treatment
outcomes are important to describe. This includes meth-
ods used to increase the distension of the lower extremity
veins, such as pretreatment ambulation, patient position-
ing maneuvers, temperature adjustments to the proce-
dure room, use of tourniquets, or pharmacologic maneu-
Moderate  2 Severe  3
stricting
ring
Daily, moderate activity
limitation, occasional
analgesics
Daily, severe limiting
activities or requiring
regular use of
analgesics
nch Multiple: GSV varicose
veins confined to calf
or thigh
Extensive: thigh and calf
or GSV and SSV
distribution
y Afternoon edema,
above ankle
Morning edema above
ankle and requiring
activity change,
elevation
d in
own)
Diffuse over most of
gaiter distribution
(lower 1/3) or
recent pigmentation
(purple)
Wider distribution
(above lower 1/3),
recent pigmentation
ited to
ound
Moderate cellulitis,
involves most of
gaiter area (lower
2/3)
Severe cellulitis (lower
1/3 and above) or
significant venous
eczema
leolar Medial or lateral, less
than lower 1/3 of
leg
Entire lower 1/3 of leg
or more
2 2
3 mo, 1year Not healed 1 year
2-6 cm diameter 6-cm diameter
f Wears elastic stockings
most days
Full compliance:
stockings  elevation 1
ot re
requi
d bra
ins
le onl
limite
ld (br
s, lim
rea ar
-mal
eter
use overs such as the administration of vasodilators. The
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also important to indicate.
Method of vein access, intraprocedural imaging,
and anesthesia. The method of venous entry—percutane-
ous, surgical cutdown, or venotomy—should be stated.
Imaging guidance for venous access, administration of
anesthetic injections, and monitoring of other aspects of
the procedure that is provided by ultrasound guidance,
fluoroscopic guidance, or a combination should be re-
ported. The type of access system (eg, micropuncture sys-
tem vs larger needle) is important to report. The precise
location of the percutaneous access site(s) is important to
indicate as well as the reason for selection of this point (eg,
absence of reflux, potential access difficulties below a cer-
tain point, and multiple large tributaries). Tumescent an-
esthesia is usually administered using a dilute local anes-
thetic to provide local anesthesia, protect surrounding
tissues (including adjacent nerves and overlying skin) from
the thermal injury, and mechanically collapse the vein to
decrease the distance between the catheter-based heat
source and the vein walls and thereby enable nonthrom-
botic ablation of the vein.3 The concentration, volume, and
method of administration (ie, hand-injection or mechanical
device) of local anesthetic drugs should therefore be de-
scribed. The use of fluoroscopy or venography must be
reported.
Method of endovenous ablation. For thermal abla-
tion techniques, the type of energy (endovenous laser or
radiofrequency) along with the manufacturer of the device
should be reported. The energy level (power in watts), time
of energy deployment (seconds), mode of delivery (pulsed
or continuous mode), and total amount of energy emitted
must be reported. If a pulsed mode is used during en-
dovenous laser ablation, the duration and frequency of the
pulse should be noted.
For radiofrequency, temperature of the catheter–vein
interface, size of the catheter (6F, 8F), catheter and gener-
ator model, rate of catheter pull-back in cm/min, and total
treatment time should be reported.
For chemical ablation techniques, the concentration,
type of sclerosant (including manufacturer), and volume of
the sclerosing agent must be reported. If a foam solution is
used, the foaming technique should be recorded.
The starting point, ending point, and total length of
the ablated segment should be reported in a quantitative
fashion (eg, from 1 cm below the saphenofemoral junction
to 1 cm above the puncture site; total, 40 cm), and for GSV
ablation in relation to groin tributaries (ie, below epigastric
vein).
The type and timing of postprocedure care such as
compression therapy should also be reported. The class and
type of compression therapy and activity restrictions should
be reported.
Adjunctive procedures. Adjunctive procedures such
as sclerotherapy and stab phlebectomies are commonly
used in patients undergoing EVA. Because of their influ-
ence on treatment outcomes, the use and timing of any
adjunctive procedures used at the time of EVA or beforethe initial outcomes assessment should be described. Ad-
ministration of sclerosant solution through the vascular
sheath encasing the laser or radiofrequency probe should
be reported. The type of sclerosant, concentration, volume,
and foaming technique for foam sclerotherapy should be
noted. It should also be clear whether adjunctive proce-
dures were intended as part of the initial treatment ap-
proach.
OUTCOMES ASSESSMENT
Clinical research studies on EVA may be generally
categorized into two types: clinical outcome studies and
technology assessment studies.
Clinical outcomes studies. These studies are de-
signed to assess the clinical efficacy and to verify the safety
of EVA procedures and are expected to quantify the impact
of therapy on clinical outcomes that are meaningful to
patients, such as:
1. relief of presenting symptoms,
2. frequency of skin ulcer healing and time to recurrence,
3. prevention of progression of chronic venous insuffi-
ciency,
4. improvement in quality of life, and
5. improvement in cosmesis, or a combination of these.
EVA may succeed in achieving all, some, or none of
these goals; similarly, EVA may alleviate all, some, or none
of the presenting symptoms. It is therefore important for
authors to define the primary clinical intent of the proce-
dure and to adjudicate success or failure by this criterion.
The primary clinical intent must be a clinical outcome of
importance to patients (eg, relief of the dominant present-
ing symptom) rather than an anatomic/imaging outcome
(eg, ultrasound-proven occlusion of the target vein). Other
end points of interest may also be reported, such as the
continued need for compression stockings and anti-
inflammatory medications after EVA and the need for
additional endovenous or surgical procedures.
Because causation of clinical outcomes is generally im-
plied as related to treatment, anatomic and imaging out-
come at the same follow-up points must be reported.
Technology assessment studies. These studies are
designed to answer specific technical questions about a new
treatment modality before embarking on full-scale clinical
outcomes studies. For such studies, it is acceptable to
report an anatomic or imaging outcome (eg, successful
ultrasound-proven ablation of the target vein) as the pri-
mary outcome, but the authors must limit their conclusions
accordingly and no mention of clinical efficacy may be
made unless a clinical outcome was systematically evalu-
ated. Because the specific goals of therapy will vary among
patients, investigators should report outcomes in as many
of the following relevant categories as possible.
Assessment of treatment effectiveness—symptom
relief. A number of methods may be used to report treat-
ment success in relieving presenting symptoms. In general,
the use of validated patient-reported measures of venous
symptom status is preferred over “homemade” scales or
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disease-specific validated scales designed to provide an as-
sessment of venous symptoms (eg, VEINES-Sym, Aber-
deen Varicose Vein Score, and the Charing Cross Venous
Ulcer Score). Authors may also focus on objectively docu-
menting improvement in one or more specific symptoms;
for example, validated pain scales such as a Likert scale may
be used to assess lower extremity pain, although pain and
discomfort are routinely addressed in the above QOLmea-
sures. Such assessments may be supplemented by objective
measures of clinical improvement that are based upon
physician assessment of clinical signs (eg, measurement of
leg circumferences in standardized fashion for assessment
of lower extremity swelling), but determination of treat-
ment success should not rely exclusively on physician as-
sessments because they may or may not correlate with
clinical improvement, which is meaningful to patients.
Assessment of treatment effectiveness—disease se-
verity and quality of life. Presenting symptoms andQOL
may improve rapidly after EVA, but meaningful evaluation
of the progression of chronic venous insufficiency needs a
significantly longer time. Clinical follow-up should there-
fore be graded as short-term (1 year), mid-term (1 to 3
years), or long-term (3 years).
Although the CEAP system is a useful descriptive tool,
it is thought to have toomany static elements to be effective
in monitoring change in disease status with treatment.27
For this reason, a number of alternative scoring systems
have been developed and partially validated for assessment
of venous disease severity in patients with chronic venous
insufficiency. The American Venous Forum has recom-
mended use of the VCSS to quantify the clinical severity of
venous disease (Table II). The VCSS is based on physician
assessment of the presence and severity of nine common
stigmata of chronic venous disease and the use of compres-
sion stockings. VCSS scores correlate well with CEAP
clinical class and with the presence of abnormalities in the
venous system documented with ultrasound imaging.28-30
For studies that focus primarily on patients with venous
ulcers, there also exist measures targeted to this sub-
group.15,16
It is important to assess QOL in patients with venous
insufficiency because it provides valuable information on
the patient-perceived burden of illness. When QOL is
assessed, a generic QOL measure, such as the Medical
Outcomes Study Short Form 36 (SF-36) measure, and a
venous disease–specific QOL measure should be used. In
recent years, a number of venous disease–specific QOL
measures have been developed and at least partly validated;
three are listed here:
● The VEINES-QOL/Sym consists of 26 question
items that measure venous symptoms, limitations in
daily activities due to venous disease, psychologic im-
pact of venous disease, and change over time. The
VEINES-QOL/Sym has undergone comprehensive
and rigorous psychometric evaluation and is accept-
able, reliable, valid, and responsive for use as a patient-reported measure of outcome in chronic venous dis-
ease.11,13,17
● The CIVIQ-2 is a 20-question survey that has been
validated for use in patients with chronic venous dis-
ease and has been used in a previous randomized trial
comparing EVA with surgical therapy.18,19 Response
to each question is rated on a 5-point scale and is
classified in one of four dimensions: Pain, Physical,
Social, or Psychological. The scores on the four dimen-
sions are combined to form a single global QOL
score.18
● The Aberdeen QOL is a 15-question survey that has
also been validated for use in patients with chronic
venous disease.31
The Charing Cross Venous Ulcer scale likely has less
utility in the population treated by EVA but is certainly
pertinent for those focused on this aspect of the chronic
venous disease.15
Assessment of treatment effectiveness—cosmesis.
Successful treatment of venous reflux commonly leads to
complete disappearance or marked reduction in the size
and visibility of varicose veins. This effect of therapy often
enhances patient satisfaction and may lead to improve-
ments in both body image and social functioning, which are
comparable with those of cosmetically directed interven-
tions in other body areas. Quantification of these effects in
future EVA studies is expected. In general, the use of
validated measures of body image, social functioning, and
patient satisfaction, such as have been used for other forms
of cosmetic intervention, is recommended rather than the
use of “homemade” scales. However, because such mea-
sures have not yet been validated for use in varicose vein
populations, recommendations for reporting in this area
cannot be firmly made at this time. It is hoped that future
versions of this document will be able to provide greater
guidance in this regard.
The assessment of recurrent symptomatic or asymp-
tomatic varicosities remains controversial. Use of a vali-
dated classification, such as Recurrent Varicose Veins after
Surgery32 should be encouraged. However, a clear and
reliable way to discriminate between persistent (residual)
veins, “true recurrences,” and varicose veins developed as a
result of disease progress remains subject to future investi-
gation.
Assessment of treatment effectiveness—anatomic/
imaging end points. EVA is believed to lead to improved
clinical outcomes by eliminating flow in the target vein,
enabling reduction in venous hypertension. To properly
determine whether treatment failures are due to inability of
the technology being evaluated to ablate the vein, use of
suboptimal treatment parameters, or other factors, it is
therefore important to know if successful ablation of the
vein was actually achieved. Because EVA may lead to com-
plete ablation or varying degrees of partial ablation of the
vein, it is also important to report the extent of successful
ablation. The exact anatomic result that correlates with
improved long-term clinical outcomes has not been scien-
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cess should be defined as successful ablation of the target
vein, as demonstrated by complete lack of flow or disap-
pearance of vein by duplex ultrasound imaging in the entire
treated segment.
Reporting the length of patent GSV below the saphe-
nofemoral junction after ablation, as measured on the
postprocedure ultrasound scan, provides important infor-
mation on the relation between the treatment starting
point and the point of achieved ablation. This can be
different for different modalities. There also may be a
difference in long-term outcome in patients who have no
patent GSV or a 1-cm stump compared with a patient with
a 5-cm length of patent GSV.
If complete ablation has not been achieved, the ana-
tomic extent of the open segment, presence or absence of
reflux, and time of flow reappearance must be reported.
Early failures (3 days from procedure) may indicate tech-
nical failures, whereas late failures can be result of recanali-
zation.
In some patients, successful ablation of a target reflux-
ing vein results in a reduction in size of other initially
refluxing veins, with subsequent restoration of unidirec-
tional flow. For this reason, it may be useful to report the
presence or absence of reflux in other ultrasound-evaluable
major lower extremity veins as well.
Although more studies are needed to more completely
validate its utility, the Venous Segmental Disease Score
(VSDS, Table III) enables this information to be repre-
sented on a continuous scale with subsequent calculation of
an overall “reflux score,”11,28,30
Uniform points for clinical and duplex ultrasound
follow-up are highly desirable. The most common being
within the first 3 days, at 1 month, 1 year after treatment,
and annually thereafter. The performance of an early post-
procedure ultrasound scan at some point 1 month after
Table III. Venous Segmental Disease Score
Reflux Score Obstruction Score
Small saphenous ½
Great saphenous 1 Great saphenous (only
if thrombosed from
groin to below
knee)
1
Perforators, thigh ½
Perforators, calf 1
Calf veins, multiple 2 Calf veins, multiple 1
Posterior tibial vein
alone
1
Popliteal vein 2 Popliteal vein 2
Femoral vein 1 Femoral vein 1
Profunda femoris vein 1 Profunda femoris vein 1
Common femoral vein
and above
1 Common femoral 2
Iliac vein 1 Inferior vena cava 1
Maximum reflux score 10 Maximum obstruction
score
10treatment is essential and must be reported. For assessmentof short-term (1 year), mid-term (1 to 3 years), or long-
term (3 years) outcomes, duplex results at the longest
follow-up should also be reported.
Assessment of treatment effectiveness—terminol-
ogy and definitions. Reports of long-term results should
use uniform terminology:
a. Recanalization (with or without reflux): documentation
of flow in a previously occluded vein.
b. Neovascularization: presence of multiple small tortuous
connections between the saphenous stump or the fem-
oral vein and the residual saphenous vein or its tributar-
ies (new, or pre-existing dilated vessels outside the
venous wall).
c. Primary ablation: ablation after initial treatment.
d. Primary assisted ablation: successful retreatment of an-
atomic recanalization before clinical failure has oc-
curred.
e. Secondary (retreatment) ablation: successful retreat-
ment of patients with anatomic and clinical failure.
Assessment of treatment efficacy—recommendations.
Authors must explicitly state whether the study is a tech-
nology assessment study or a clinical outcomes study.
For clinical outcomes studies, authors must report the
proportion of patients for whom the primary clinical intent
of EVA is symptom relief, venous ulcer healing, prevention
of progression of chronic venous insufficiency, and im-
provement in cosmesis. Authors must adjudicate the overall
clinical success or failure of EVA according to whether the
primary clinical intent of the procedure was achieved and
must report the proportion of patients in which this oc-
curred.
Anatomic and imaging outcomes (eg, successful ultra-
sound-proven target vein ablation) may be used as the
primary outcome for technology assessment studies but not
for clinical outcomes studies. Additional reporting of the
proportions of patients in whom symptom relief, ulcer
healing, regression of chronic venous insufficiency, or cos-
metic improvement was achieved, or a combination of
these is highly recommended.
Assessment of treatment safety. Performance of
EVA may be associated with a number of early and late
complications. Any invasive therapy can produce an infec-
tious complication, and those that require conscious seda-
tion carry risks of cardiorespiratory compromise. If venog-
raphy is used to guide therapy, allergic reactions or renal
failure, defined as a20% increase in serum creatinine level,
may occur.33 Deep vein thrombosis (DVT) or pulmonary
embolism, or both, occur with rare frequency in patients
treated with EVA andmust be reported along with anatom-
ical location and extent of the thrombus.34 Other compli-
cations may include skin burns, paresthesias or other nerve
injuries, and superficial thrombophlebitis in the treated
vein or in a tributary.35
All adverse events occurring during or 30 days after
the EVA plus adjunctive procedures must be considered
procedure-related. The SIR classification system for grad-
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when reporting results.
Assessment of resource utilization. A rigorous anal-
ysis of EVA costs should include the cost of all procedures,
devices, medications, and the inpatient treatment required;
the cost of use of the procedure suite used; the costs of
immediate and long-term complications and recovery time;
and the costs of long-term monitoring and treatment.36-38
COMPARISON BETWEEN TREATMENT
GROUPS
The study design, sample size, statistical power, and
statistical analyses must be reported as well as institutional
review board status and funding source. Consultation with
a statistician in the methodology of the study design and
statistical analysis is recommended before starting the
study. For comparative studies, blinding of the outcomes
assessors should be used whenever possible. A description
of all methods used to minimize bias in the study is recom-
mended.
Patients in comparative studies should be stratified by
the anatomic location of the target vein and baseline clinical
disease severity because these key factors may influence
treatment outcomes.
Primary statistical analyses must be reported based on
intention-to-treat and per-protocol analyses. With an
intention-to-treat approach, subjects are analyzed with the
group to which they are initially allocated regardless of
whether they actually received the treatment or dropped
out of the study. Per-protocol analysis considers only those
patients who actually received the intended treatment. Dis-
cussions of significance should incorporate the study design
limitations. If the study conclusions are based on analysis of
surrogate (ie, nonclinical) outcomes, they should be tem-
pered accordingly.
STATISTICAL ANALYSIS
Appropriate statistical methods of assessing outcomes
should be used. For long-term follow-up studies, life-table
analysis is an established standard. In comparison studies,
techniques allowing adjustment for covariants are preferen-
tial, such as logistic regression, generalized linear model,
and Cox proportional hazards model.
Numeric information presented in the report should be
sufficient for an independent analysis of major findings.
Table IV. Definition of complications
Minor complications
No therapy, no consequence
Nominal therapy, no consequence; includes overnight
admission for observation only
Major complications
Require therapy, minor hospitalization (48 hours)
Require major therapy, unplanned increase in level of care,
prolonged hospitalization (48 hours)
Permanent adverse sequelae
DeathIdeally, the study database should be available for access.CONCLUSION
Endovenous ablations are promising treatment options
for lower extremity venous disease. It is the purpose of this
document to enhance the uniformity of research reporting
on these procedures. A summary of the recommendations
and requirement for reporting is provided in Table V.
REFERENCES
1. Callam MJ. Epidemiology of varicose veins. Br J Surg 1994;81:167-
173.
2. Bone C. Tratamiento endoluminal delas vaarices con laser de diodo:
studio preliminary. Rev Patol Vasc 1999;5:35-46.
3. Min RJ, Khilnani N, Zimmet SE. endovenous laser treatment of saphe-
nous vein reflux: long term results. J Vasc Interv Radiol 2003;14:991-
996.
4. Chandler JG, Pichot O, Sessa C, Schuller-Petrovic S, Osse FJ, Bergan
JJ. Defining the role of extended saphenofemoral junction ligation: a
prospective comparative study. J Vasc surg 2000;32:941-53.
5. Merchant RF, DePalma RG, Kabnick LS. Endovascular obliteration of
Table V. Recommendations for reporting standards
Required Recommended
Pre-EVA evaluation (Section 1)
Patient population □
Age, gender, race □
Clinical indication for EVA □
Anatomic location of treated
vein
□
CEAP staging □
Clinical Severity Score □
Study design
Inclusion criteria □
Exclusion criteria □
Comorbid diseases □
Functional status and QOL □
Pretreatment imaging □
Primary reason for treatment □
EVA description (Section 2)
Pre-treatment preparation □
Method of vein access □
Intraprocedural imaging □
Device or chemical agent
description
□
Energy source, duration □
Total energy deposited, or dose
of sclerosant
□
Adjunctive techniques □
Anesthesia □
Length and diameter of vein □
Post-EVA evaluation (Section 3
and 4)
Complications
Immediate □
30-day □
Follow-up imaging at regular
intervals
□
Follow-up of clinical status □
QOL assessment □
Uniform duration of follow-up □
Need for additional procedures □
Costs/cost effectiveness □
Primary outcome □
EVA, Endovenous ablation; QOL, quality of life.saphenous reflux: a multi-center study. J Vasc Surg 2002;35:1190-6.
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 3 Kundu et al 5896. Pichot O, Sessa C, Chandler JG, Nuta M, Perrin M. Role of duplex
imaging in endovenous obliteration for primary venous insufficiency. J
Endovasc Ther 2000;7:451-9.
7. Kabnick LS, Merchant RF. Twelve and twenty-four month follow-up
after endovascular obliteration of saphenous vein reflux: a report from
the multi-center registry. J Phlebol 2001;1:17-24.
8. Lurie F, Creton D, Eklof B, Kabnick LS, Kistner RL, Pichot O,
Schuller-Petrovic S, Sessa C. Prospective randomized study of en-
dovenous radiofrequency obliteration (closure procedure) versus liga-
tion and stipping in a selected patient population (EVOLVeS Study). J
Vasc Surg 2003;38:207-214.
9. Lurie F, Creton D, Eklof B, Kabnick LS, Kistner RL, Pichot O, et al.
Prospective randomized study of endovenous radiofrequency oblitera-
tion (closure) versus ligation and vein stripping (EVOLVeS): two-year
follow-up. Eur J Vasc Endovasc Surg 2005;29:67-73.
10. Eklof B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner
RL, et al; for the American Venous Forum International Ad Hoc
Committee for Revision of the CEAP Classification. Revision of the
CEAP classification for chronic venous disorders: consensus statement.
J Vasc Surg 2004;40:1248-52.
11. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner
MH, Moneta GL. Venous severity scoring: a adjunct to venous out-
come assessment. J Vasc Surg. 2000 Jun;31:1307-12.
12. Kakkos SK, RiveraMA,MatsagasMI, LazaridesMK, Robless P, Belcaro
G, et al. Validation of the new venous severity scoring system in varicose
vein surgery. J Vasc Surg 2004;39:696-7.
13. Lamping DL, Abenhaim L, Kurz X, Schroter S, Kahn SR. Measuring
quality of life and symptoms in chronic venous disorders of the leg:
development and psychometric evaluation of the VEINES-QOL/Sym
questionnaire. Qual Life Res 1998;7:621-2.
14. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluation of
outcomes in chronic venous disorders of the leg: development of a
scientifically rigorous, patient-reported measure of symptoms and qual-
ity-of-life. J Vasc Surg 2003;37:410-9.
15. Smith JJ, Guest M, Greenhalgh RM, Davies AH. Measuring the quality
of life in patients with venous ulcers. J Vasc Surg 2000;31:642-9.
16. Franks PJ, Moffatt CJ. Health related quality of life in patients with
venous ulceration: use of the Nottingham health profile. Qual Life Res
2001;10:693-700.
17. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative
responsiveness of generic and specific quality-of-life instruments. J Clin
Epidemiol 2003;56:52-60.
18. Kahn SR,Milan CE, LampingDL, Kurz X, Bérard A, Abenhaim LA; for
the VEINES Study Group. Relationship between clinical classification
of chronic venous disease and patient-reported quality of life: results
from an international cohort study. J Vasc Surg 2004;39:823-8.
19. Launois R, Reboul-Marty J, Henry B. Construction and validation of a
quality of life questionnaire in chronic lower limb venous insufficiency
(CIVIQ). Qual Life Res 1996;5:539-54.
20. Merchant RF, Pichot O. Long term outcomes of endovenous radiofre-
quency ablation of saphenous reflux as a treatment for superficial venous
insufficiency. J Vasc Surg 2005;42:502-9.
21. Caggiati A, Bergan JJ, Gloviczki P, Jantet G, Wendell-Smith CP,
Partsch H, for the International Interdisciplinary Consensus Commit-
tee on Venous Anatomical Terminology. Nomenclature of the veins ofthe lower limbs: an international interdisciplinary consensus statement.
J Vasc Surg 2002;36:416-22.
22. Caggiati A, Bergan JJ, Gloviczki P, Eklof B, Allegra C, Partsch H, for
the International Interdisciplinary Consensus Committee on Venous
Anatomical Terminology. Nomenclature of the veins of the lower limb:
extensions, refinements, and clinical application. J Vasc Surg 2005;41:
719-24.
23. Min RJ, Khilnani NM, Golia P. Duplex ultrasound evaluation of lower
extremity venous insufficiency. J Vasc Interv Radiol 2003;14:1233-41.
24. Porter JM, Rutherford RB, Clagett GP, Cranley JJ, O’Donnell TF,
Raju S, et al. Reporting standards in venous disease. J Vasc Surg
1988;8:172-81.
25. Nicolaides AN. Investigation of chronic venous insufficiency: a consen-
sus statement Circulation 2004;102:E126-63.
26. Van Bemmelen PS, Bedford G, Beach K, Strandness DE. Quantitative
segmental evaluation of venous valvular reflux with DUS ultrasound
scanning. J Vasc Surg 1989;10:425-31.
27. Vedantham S, Grassi CJ, Ferral H, Patel NH, Thorpe PE, Antonacci
VP, et al; for the Technology Assessment Committee of the Society of
Interventional Radiology. Reporting standards for endovascular treat-
ment of lower extremity deep vein thrombosis. J Vasc Interv Radiol
2006;17:417-34.
28. Rutherford RB, Padberg FT, Comerota AJ, Kistner RL, Meissner MH,
Moneta GL. Venous outcomes assessment. In: Gloviczki P, Yao JST,
editors. Handbook of venous disorders. 2nd ed. Guidelines of the
American Venous Forum. Great Britain: Arnold; 2001. p. 497-508.
29. Meissner M, Natiello CM, Nicholls SC. Performance characteristics of
the Venous Clinical Severity Score. J Vasc Surg 2002;36:889-95.
30. Ricci MA, Emmerich J, Callas PW, Rosendaal FR, Stanley AC, Naud S,
et al. Evaluating chronic venous disease with a new venous severity
scoring system. J Vasc Surg 2003;38:909-15.
31. Janet G. RELIEF Study: first consolidated European data. Angiology
2000;51:31-7.
32. Perrin M, Allaert FA. Intra- and inter-observer reproducibility of the
Recurrent Varicose Veins after Surgery (REVAS) classification. Eur J
Vasc Endovasc Surg 2006;32:326-32.
33. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, et al.
Guidelines for the reporting of renal artery revascularization in clinical
trials. J Vasc Interv Radiol 2002;13:959-74.
34. Mozes G, Kalra M, Carmo M, Swenson L, Gloviczki P. Extension of
saphenous thrombus into the femoral vein: a potential complication of
new endovenous ablation techniques. J Vasc Surg 2005;41:130-5.
35. Sichlau MJ, Ryu RK. Cutaneous thermal injury after endovenous laser
ablation of the great saphenous vein. J Vasc Interv Radiol 2004;15:
865-7.
36. Finkler SA. The distinction between cost and charges. Ann Intern Med
1982;96:102-9.
37. Eisenberg JM. Clinical economics: a guide to the economics of clinical
practices. JAMA 1989;262:2878-86.
38. Powe NR. Economic and cost-effectiveness investigations of radiologic
practices. Radiology 1994;192:11-8.Submitted Apr 25, 2007; accepted May 14, 2007.
